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Abstract 
BACKGROUND: Alzheimer’s disease (AD), the most common cause of dementia, is evolving to become a 
threatening epidemy of the 21
st
 century. Only 21% of the predicted number of AD patients in Macedonia have 
been diagnosed and treated, which means that almost 80% are underdiagnosed or misdiagnosed. Apolipoprotein 
E gene (APOE) is recognised as the strongest genetic risk factor for sporadic AD. Whether and when Alzheimer’s 
disease develops, depends on the very complex interaction between genetic and modifiable risk factors. It has 
been known that vascular factors like hypertension, diabetes mellitus, hypercholesterolemia and obesity increase 
the risk of developing both AD, vascular dementia and mixed AD and vascular pathology 
AIM: This study aims to evaluate the influence of APOEε4 allele presence and modifiable vascular risk factors 
(hypertension, diabetes mellitus and dyslipidemia) as prognostic and risk factors for AD and their influence on the 
age of onset of AD symptoms among 144 AD patients from Macedonia.  
MATERIAL AND METHODS: Study group of a total of 144 patients diagnosed with AD was evaluated. APOE 
genotyping was performed using APOE haplotype-specific sequence specific-primer (SSP)-PCR (Polymerase 
Chain Reaction) methodology. The non-standardized questionnaire was used to obtain information about 
demographics, lifestyle and modifiable risk factors that could influence disease onset and phenotype. 
RESULTS: Statistically significant association was found between the presences of APOEε4 allele in AD group 
versus controls. The presence of APOEε4 allele increases the risk of developing AD in a 3-fold manner. The 
average age of disease onset in the ε4 carrier group was 67.2 ± 8.3 and in the ε4 non-carrier group 69.7 ± 9.4. 
This confirms that the presence of APOEε4 allele shifts towards earlier disease onset, though the difference is not 
statistically significant. Out of the vascular risk factors, only hypertension was significantly associated with earlier 
AD onset. Out of total 144 patients, in 22.9% the first symptom onset was before the age of 65, that can be 
considered as early onset Alzheimer’s Disease (EOAD), which is much higher than 5% for EOAD as most of the 
studies report. 
CONCLUSIONS: The average age of disease onset of 68.4 years could be considered earlier than the average 
age of AD onset worldwide. Out of all the vascular risk factors analysed in this study, only hypertension and 
dyslipidemia were found to significantly increase the risk for developing AD and only the presence of hypertension 
influences the age of onset, shifting towards earlier disease onset. Public awareness campaigns should be 
organised to influence general population knowledge about Alzheimer’s disease, early recognition and the 
influence of modifiable vascular risk factors. 
 
Introduction 
 
Alzheimer’s disease (AD), the most common 
cause of dementia, is evolving to become a 
threatening epidemy of the 21
st
 century, even though 
not an infectious disorder. In 2015, 47 million people 
had dementia worldwide, with predictions that this 
number would at least triple by the year of 2050, 
estimating that there will be around 131 million living 
with dementia, mostly AD [1]. A disease that was in 
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details described by Alois Alzheimer in 1906 and was 
considered to be a rare disease at that time is about 
to become a global medical and social problem, 
mostly affecting people living in low- and middle-
income countries. Even though the exact aetiology 
and pathogenesis of Alzheimer’s disease is still an 
unrevealed challenge for the neuroscience, it is well 
known that old age is a major risk factor for AD. With 
better medical treatment for cardiovascular, cancer 
and infectious disorders and a growing number of 
ageing populations worldwide, the rapid expansion of 
Alzheimer’s disease shortly is expected.  
The standardized age prevalence for 
dementia worldwide is 5-7% for aged 60 years and 
more [1], that assumes that there are around 20,000 
people living with AD in Macedonia (according to 
State Statistical Office, R. Macedonia 2.4.15.10/821, 
there are around 400,000 people aged 60 and more 
living in Macedonia). According to the data from 
Health Insurance Fund of Macedonia for donepezil 
(acetylcholinesterase inhibitor, registered for 
treatment of AD) prescriptions in 2017, only 4,200 
patients were treated. This assumes that only 21% of 
the predicted number of AD patients in Macedonia 
have been diagnosed and treated, which means that 
almost 80% are underdiagnosed or misdiagnosed.  
Two forms of Alzheimer’s Disease are 
recognised according to the age of onset. Early-onset 
Alzheimer’s disease (EOAD) that begins before the 
age of 65 and presents only 5% of overall AD 
patients. EOAD patients usually have positive family 
history for the disease, and in half of the EOAD, that is 
in only 1- 2% of the total AD patients, the disease 
develops due to a monogenic deterministic mutation 
in one of the three known genes amyloid precursor 
protein (APP), prseniline1 (PSEN1) or presenilin2 
(PSEN2) gene.  
According to another study, the percentage of 
autosomal dominant inherited forms of EOAD is even 
smaller, only around 7% of all early-onset cases [2]. 
The other 95% of AD patients, have disease onset at, 
or after the age of 65, late-onset Alzheimer’s disease 
(LOAD), and present the majority of AD patients [1]. 
LOAD is sporadic, occurring in individuals with genetic 
susceptibility in complex interaction with 
environmental and lifestyle modifiable risk factors. 
Apolipoprotein E gene (APOE) is recognised 
as the strongest genetic risk factor for LOAD. It has 
three allelic variants ε2, ε3 and ε4. It is the presence 
of APOEε4 allele that increases the risk for LOAD. 
According to several studies, the presence of APOEε4 
allele in LOAD patients is 50-60% compared to 20-
25% in healthy older adults respectively. The 
presence of ε4 allele increases the risk of developing 
AD in a dose-dependent manner. APOEε4/ε4 
homozygosity increases the risk for developing AD 
14-fold, and APOE ε3/ε4 heterozygosity increases the 
lifetime risk for AD, 4-fold in comparison to ε3 
homozygosity [3], [4], [5]. The presence of APOEε4 
allele shifts the age of disease onset approximately 5 
to10 years earlier in heterozygosity, and up to 10-20 
years earlier in homozygosity [2]. APOEε4 allele 
frequency is highly variable in different population and 
ethnic groups [6]. The worldwide frequency of ε2, ε3 
and ε4 alleles is 8.4%, 77.9% and 13.7%, 
respectively, but in AD patients the ε4 frequency 
increases up to 40% [7]. When discussing the APOE 
gene as a risk factor for AD, it must be stressed that it 
only influences the individual’s genetic susceptibility, 
but it is not deterministic as the previously mentioned 
three gens. That means, that even if homozygosity for 
ε4 is present, it only increases lifetime risk, but does 
not mean that AD would certainly develop. Whether 
and when Alzheimer’s disease develops depends on 
the very complex interaction between genetic and the 
modifiable risk factors. It has been known that 
vascular risk factors like hypertension, diabetes 
mellitus, hypercholesterolemia and obesity increase 
the risk of developing both AD, vascular dementia and 
mixed AD and vascular pathology [6].  
This study aims to evaluate the influence of 
APOEε4 allele presence and modifiable vascular risk 
factors (hypertension, diabetes mellitus and 
dyslipidemia) as prognostic and risk factors for AD 
and their influence on age of symptoms onset among 
144 AD patients from Macedonia.  
 
 
Material and Methods 
 
The study group includes 144 subjects that 
were diagnosed in the dementia outpatient clinic at 
the University Clinic of Neurology-Skopje and 
dementia centre at the University Clinic of Psychiatry-
Skopje within the period from 2016 to 2018. All 
subjects fulfilled criteria for probable Alzheimer’s 
dementia according to standard diagnostic criteria [8]. 
A standard procedure of blood sample collection was 
performed for DNA isolation. APOE genotyping was 
performed in the genetic laboratory ”Prof. Dr Georgi 
Efremov”, Macedonian Academy of Arts and 
Sciences. APOE haplotype-specific sequence 
specific-primer (SSP)-PCR (Polymerase Chain 
Reaction) methodology was used to determine the 
three main APOE isoforms. The non-standardized 
questionnaire was used to obtain information about 
demographics, lifestyle and modifiable risk factors that 
could influence disease onset and phenotype. We 
used an age-matched control group to evaluate ε4 
allele frequency.  
Written informed consent was obtained from 
all subjects included in the study group and from the 
control group. 
Statistical analysis in STATISTICA 7.1, SPSS 
20.0 were done, using chi-square test, t-test and 
univariate and multiple logistic regression analyses. 
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Results 
 
A study group of a total of 144 patients 
diagnosed with AD was evaluated. APOEε4 allele 
carriers were found to be 72 out of 144 AD patients, 
that is 50.0%, compared to the control group where 
APOEε4 allele carriers were 21 out of 90 individuals, 
which makes 23.3%. Statistically, a significant 
association was found between the presence of 
APOEε4 allele and AD, p < 0.05 (Pearson Chi-square 
= 16.8103, p = 0.000041). 9% of all AD patients in our 
study group were APOEε4/ε4 homozygotes, versus 
only 1 subject (1.1%) in the control group. Calculated 
APOEε4 allele frequency was 30.14% in the AD 
patients’ group, compared to 12.22% in the control 
group, which is statistically significant (p < 0.05). 
 
APOE genotype/AD patients Count % 
е3-е3 67 46.5 
е3-е4 59 41.0 
е2-е3 4 2.8 
е4-е4 13 9.0 
missing 1 0.7 
total 144 100.0 
APOE genotype/controls 
е3-е3 60 66.7 
е3-е4 19 21.1 
е2-е3 9 10.0 
е2-е4 1 1.1 
е4-е4 1 1.1 
total 90 100.0 
 
Figure 1: APOE genotype distribution among AD patients and 
controls 
 
According to the analysis in our study group, 
the presence of APOEε4 allele increases the risk of 
developing AD in a 3-fold manner [OR-3.3320 
(1.8502-6.0005)]. APOEε4 undoubtedly has 
influenced the genetic susceptibility in sporadic AD 
patients and has influenced the disease manifestation. 
The average age of onset of Alzheimer’s 
disease in our study group, which makes the first AD 
research till now in this geographic region and among 
this ethnic population is 68.4 years. This can be 
considered lower in comparison to Nussbaum reports 
that the average age of dementia onset is around 80 
years [2]. 
One of the explanations could be that younger 
patients are referred to the dementia outpatient clinic 
at the University Clinic of Neurology and dementia 
centre at the University Clinic of Psychiatry, and older 
patients with Alzheimer’s disease are under or miss 
diagnosed. Unfortunately, the public awareness about 
Alzheimer’s disease in Macedonia is still low, and 
forgetfulness is still considered as a part of normal 
ageing. 
Even though this might seem like a logical 
explanation, it is unlikely that only younger AD 
patients were referred to tertiary level, as this 
research lasted for 2 years, and in the meantime, a lot 
of educational workshops for family doctors were 
organised influencing the professional awareness 
about AD. If we conclude that sporadic AD in 
Macedonia has a somewhat earlier onset than in other 
population, it is important to identify the causes. As 
the presence of APOEε4 allele not only increases the 
genetic susceptibility for AD in a dose-dependent 
manner but also influences the age of dementia onset, 
shifting to earlier onset in ε4 carriers, this might be 
one possibility. 
 
Figure 2: Mean age distribution among APOEε4 non-carriers-I and 
APOEε4 carriers-II 
 
When we divided AD patients into two groups 
according to their APOEε4 status, ε4 carriers and ε4 
non-carriers, we found that average age of disease 
onset in the ε4 carrier group was 67.2 ± 8.3, and in 
the ε4 non-carrier group 69.7 ± 9.4. This confirms that 
the presence of APOEε4 allele shifts towards earlier 
disease onset, though the difference is not statistically 
significant, p > 0.05 (t-test = 1.533270, p = 0.127864). 
 
 
Discussion  
 
In our AD patients study group, out of total 
144 patients, 22.9% had the first symptom onset 
before the age of 65, that can be considered as 
EOAD, which is much higher than 5% as most studies 
report [1]. Out of those EOAD patients, APOEε4 allele 
was present in 54.5% (in 94.4% as heterozygotes, 
and 5.6% as homozygotes). 
Excluding the influence of APOEε4 on the age of 
onset we looked for the presence and influence of the 
modifiable risk factors. 
When analyzed for the association of 
modifiable vascular risk factors (hypertension, 
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diabetes mellitus and dyslipidemia) for AD in our study 
group compared to the control group, a statistically 
significant association was found for hypertension and 
p < 0.05 (Pearson Chi-square = 4.5302, p = 
0.033015) and dyslipidemia p < 0.05 (Pearson Chi-
square = 6.1103, p = 0.013439), but not for diabetes 
mellitus p < 0.05 (Pearson Chi-square = 0.0377, p = 
0.845696). Having hypertension was found to be 
associated with 1.5-fold increased risk for developing 
AD [OR = 1.8767 (1.0479-3.3615)] and dyslipidemia 
was found to be associated with 2-fold increased risk 
for AD [OR = 2.2656 (1.1749-4.3688)] in our study. 
Using multivariant logistic regression only the 
presence of APOEε4 allele was confirmed to be a 
predictor for Alzheimer’s disease.  
Correlation among age of AD onset and 
hypertension, diabetes mellitus, obesity, dyslipidemia 
and physical activity was done, showing that only 
hypertension was significantly associated with earlier 
AD symptoms onset.  
This confirms what previous studies reported 
by identifying hypertension, especially midlife 
hypertension to be one of the main modifiable risk 
factors for AD and as Winblad et al. suggest, 
pharmacological control of hypertension, implemented 
in middle-aged or younger old adults, might be 
effective in reducing the incidence of dementia [1]. 
Other population-based studies have shown that 
having multiple cardiovascular risk factors (smoking, 
hypertension, diabetes mellitus, 
hypercholesterolemia) in middle age or several years 
before dementia onset, increases the risk for 
developing AD [1], [9]. 
In conclusion, in our study group of 144 AD 
patients, a statistically significant association was 
found between the presences of APOEε4 allele in AD 
group versus controls. The presence of APOEε4 allele 
increases the risk for developing AD in a 3-fold 
manner and is the only confirmed to be a predictor for 
Alzheimer’s disease. The average age of disease 
onset of 68.4 years could be considered earlier than 
the average age of AD onset worldwide. The 
presence of APOEε4 allele shifts towards earlier 
disease onset, though the difference is not statistically 
significant. 
Out of all the vascular risk factors analysed in 
this study, only hypertension and dyslipidemia were 
found to significantly increase the risk for developing 
AD and only the presence of hypertension influences 
the age of onset, shifting towards earlier disease 
onset.  
Public awareness campaigns should be 
organised to influence general population knowledge 
about Alzheimer’s disease, early recognition and the 
influence of modifiable vascular risk factors. 
As the autosomal dominant inherited forms of 
EOAD are extremely rare, we should continue our 
research in evaluating potentially modifiable risk 
factors that influence the age of disease onset. Other 
design protocols might reveal other risk or lack of 
protective factors (such as higher levels of education, 
socialisation) that also influence the age of disease 
onset. Aggressive treatment of especially midlife 
hypertension could delay AD onset in genetically 
susceptible individuals that would aid more years to 
their life and more quality lifetime. 
Further genetic research is needed especially 
in the EOAD subgroup to evaluate the presence of the 
three deterministic monogenic mutations in APP, 
PSEN1 and PSEN2 genes as potential genetic factors 
for EOAD, even though there is no family history that 
indicates autosomal dominant trait of transmitting. 
Only two decades ago, the diagnose of Alzheimer’s 
disease in Macedonia was extremely rare and the 
term “sclerosis” was used to describe the dementia 
syndrome, which is why the general population does 
not report if someone from the family had 
forgetfulness, got lost (symptoms and signs that might 
be indicative for AD), which can mislead us in taking 
the family history. GWAS (Genome-wide associated 
study) might identify other than APOE genes, some of 
them specifically for geographic region or ethnicity, 
that might also influence genetic susceptibility, 
increase the individual risk for AD and decrease the 
age of symptoms onset. 
In times when there is no etiological treatment 
that would stop or even slow down Alzheimer’s 
disease progression, identifying individuals at risk and 
developing preventive strategies is more than 
necessary if we want to cut down the predicted 
numbers of affected population with Alzheimer’s 
dementia till the year of 2050. 
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